AVITA MedicalASX:AVH -2.50%58 PS Ratio is 1.56 as of Jul. 01, 2026, which is 77% below its 10-year median of 6.73. GuruFocus rates ASX:AVH with a GF Score™ of 58/100 and a GF Value™ of A$3.14 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 805 Medical Devices & Instruments companies, AVITA Medical ranks better than 66.71% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, AVITA Medical's share price is A$1.17.
AVITA Medical's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was A$0.75. Hence, AVITA Medical's PS Ratio for today is 1.56.
The historical rank and industry rank for AVITA Medical's PS Ratio or its related term are showing as below:
ASX:AVH'
s PS Ratio Range Over the Past 10 Years
Min: 1.27 Med: 6.73 Max: 278.74
Current: 1.61
During the past 13 years, AVITA Medical's highest PS Ratio was 278.74. The lowest was 1.27. And the median was 6.73.
ASX:AVH's PS Ratio is ranked better than 66.71% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 2.94
vs ASX:AVH: 1.61
AVITA Medical Inc revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of AVITA Medical was -8.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 23.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 28.60% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 37.00% per year.
During the past 13 years, AVITA Medical's highest 3-Year average Revenue per Share Growth Rate was 134.50% per year. The lowest was -46.80% per year. And the median was -4.90% per year.
Back to Basics: PS Ratio
AVITA Medical (ASX:AVH) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
AVITA Medical PS Ratio Related Terms
AVITA Medical PS Ratio Historical Data
* Premium members only.
The historical data trend for AVITA Medical's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, AVITA Medical's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AVITA Medical PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AVITA Medical's PS Ratio distribution charts can be found below:
* The bar in red indicates where AVITA Medical's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
AVITA Medical's Share Price of today is A$1.17. AVITA Medical's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was A$0.75.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
AVITA Medical (ASX:AVH) has a PS Ratio of 1.56 as of Jul. 01, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on AVITA Medical and its competitors. This is 77% below median its historical median of 6.73. Over the past decade, AVITA Medical's PS Ratio has ranged from 1.27 to 278.74. According to the industry distribution chart, AVITA Medical ranks #268 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 33.3%.
Is AVITA Medical's PS Ratio too high?
AVITA Medical's current PS Ratio of 1.56 is 77% below median its 10-year median of 6.73. Over the past 10 years, this metric has ranged from a low of 1.27 to a high of 278.74. The Medical Devices & Instruments industry median PS Ratio is 2.94. AVITA Medical's value of 1.56 is 46.9% below this industry median. Based on the distribution chart, AVITA Medical ranks #268 out of 805 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, AVITA Medical has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AVITA Medical's PS Ratio compare to MXCT and HYPR?
According to the Medical Devices & Instruments industry distribution chart, AVITA Medical ranks #268 out of 805 companies for PS Ratio. This puts AVITA Medical in the upper half of its industry. The industry median PS Ratio is 2.94. AVITA Medical's value of 1.56 is 46.9% below this benchmark. Historically, AVITA Medical's own PS Ratio has ranged from 1.27 to 278.74 over the past decade. While the company's 10-year median is 6.73 vs. the industry median of 2.94, AVITA Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.94, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AVITA Medical's current PS Ratio of 1.56 is 46.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on AVITA Medical and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AVITA Medical's current PS Ratio is 1.56, which is 77% below median its own 10-year median of 6.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AVITA Medical stock overvalued right now?
Based on GuruFocus' analysis, AVITA Medical (ASX:AVH) is currently considered Possible Value Trap. The stock's GF Value™ is A$3.14, compared to a current price of A$1.17 — trading 62.7% below its estimated fair value. The current PS Ratio is 1.56, which is 77% below median its 10-year median of 6.73 and 46.9% below the Medical Devices & Instruments industry median of 2.94. AVITA Medical's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For AVITA Medical (ASX:AVH), the current PS Ratio is 1.56 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AVITA Medical (ASX:AVH) Overvalued in 2026?
Based on GuruFocus' analysis, AVITA Medical stock appears to be undervalued.
The current stock price of A$1.17 is trading 62.7% below its estimated GF Value™ of A$3.14.
GuruFocus considers AVITA Medical to be Possible Value Trap.
Key valuation signals for ASX:AVH:
PS Ratio: 1.56 (77% below median its 10-year median of 6.73)
GF Value™: A$3.14 vs. price of A$1.17 (62.7% below fair value)
Industry Position: 46.9% below the Medical Devices & Instruments median (#268 of 805)
No single metric tells the full story. See the ASX:AVH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
58GF Score
Get the complete analysis for ASX:AVH
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AVH has been successfully added to your 
